Securities Class Action Filed Against Zenas BioPharma, Inc.

Strategic Insights -

Investors who purchased or acquired stock of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in connection with the company's initial public offering (IPO) on September 13, 2024, may be eligible to join a securities class action lawsuit. The lawsuit, filed in federal court, alleges that the company and its executives made false and misleading statements about the company's financial condition, causing investors to suffer damages. The law firm Faruqi & Faruqi, LLP is investigating potential claims against Zenas and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in the class action.

Key Takeaways:

  • The lawsuit alleges that Zenas' registration statement for the IPO contained false and misleading statements about the company's financial condition.
  • The complaint claims that the company and its executives overstated the amount of time it could fund its operations using existing cash and expected net proceeds from the IPO.
  • As a result, investors suffered damages when the true details about the company's financial condition entered the market.
  • The court-appointed lead plaintiff will direct and oversee the litigation on behalf of the putative class.
  • Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or choose to remain an absent class member.
  • The decision to serve as a lead plaintiff or not does not affect the ability to share in any potential recovery.

Statistics:

  • The IPO was held on September 13, 2024.
  • The lawsuit was filed in federal court.
  • The deadline to seek the role of lead plaintiff is June 16, 2025.
  • The court-appointed lead plaintiff will direct and oversee the litigation on behalf of the putative class.
  • Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or choose to remain an absent class member.

Sources:

  • Faruqi & Faruqi, LLP press release dated June 10, 2025.
  • Zenas BioPharma, Inc. (NASDAQ: ZBIO) public statement.
  • Federal Securities Class Action lawsuit filed in federal court.